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REPLY
We agree with Dr. Standing that a pediatric formulation of
bosentan is needed. The pharmaceutical development of a pediat-
ric formulation, in the form of an orodispersible tablet with a
flexible dosage of 8 to 32 mg, is currently undergoing clinical
evaluation in children in Europe and in the U.S.
However, during the course of development and validation of
the pediatric formulation, the current adult formulation of bosen-
tan was used to begin evaluation of the pharmacokinetics and
safety of bosentan in children (1). We acknowledge that we do not
describe in detail in our study (2) the technical aspects associated
with cutting the adult tablets for the treatment of children.
However, several studies have shown the adult formulation is
suitable to this situation:
1. The active bosentan substance is uniformly spread throughout
the bosentan tablet.
2. Seventy-five percent of the tablet weight is drug substance,
thereby limiting the possibility of nonuniformity of the med-
ication dose.
3. The weight of halved tablets, split with a commercially
available tablet cutter, was within European and U.S. Phar-
macopeia specifications (Actelion, personal communication,
2001). In addition, dissolution rates were measured and found
to be similar for both whole and halved tablets.
Therefore, the use of split tablets was considered appropriate for
conducting a pharmacokinetic study (1). Quartered tablets were
not tested at that time. In our study (2), we followed the sponsor’s
recommendations of using a commercially available cutter to split
the tablets, with no crushing of halved/quartered tablets, and direct
oral administration.
Whereas the pharmaceutical development of the pediatric
formulation of bosentan was ongoing, we treated children with
symptomatic pulmonary arterial hypertension (PAH) at our clinics
with the adult bosentan formulation following the sponsor’s
recommendation for dosing in children at that time (i.e., based on
a conservative extrapolation by weight of the recommended adult
dosages). Using this approach, these data demonstrated the safety
and efficacy of bosentan for pediatric PAH. However, we also
agree with Dr. Standing that pediatric dosing needs to be studied
further. We anticipate that the current evaluation of a pediatric
bosentan formulation will lead to optimal bosentan dosing regi-
mens for children with PAH.
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Limitations of Crush Technique
Ge et al. (1) reported the results of a prospective study on long-term
outcomes of “crush technique” (CT) with drug-eluting stents. This
study raises, in our opinion, two main issues.
First, as pointed out by Williams and Abbott in their editorial
(2), this study reports a clearly worse outcome as compared to
studies with “provisional T stenting” (PTS) and serious concerns
about safety profile (4.4% incidence of stent thrombosis). More-
over, the success rate in recrossing the stent struts for final kissing
balloon is not reported in the study. Because 36% of patients did
not undergo final kissing balloon postdilation, we may assume that,
at least in some of them, it was not possible to recross the stent
struts. This is an important limitation as any further therapy of
side-branch restenosis in “unrecrossable” patients (40% incidence)
becomes virtually impossible by means of percutaneous coronary
intervention (PCI). From this perspective, PTS appears also to be
superior as a second stent is needed in only 15% to 33% of cases,
and final kissing balloon is possible in 95% of cases (3).
Additionally, in case of side-branch restenosis it is always possible
to perform additional PCI. Taken together these limitations may
“crush” down the clinical role of CT, a conclusion not clearly
underlined by the investigators.
Second, the modest results of CT reported in the study by Ge
et al. (1) are not surprising. In fact, CT results in three drug-
eluting stent (DES) layers crushed on an arterial wall at a site of
high hemodynamic turbulence, with high chances of the stents’
incomplete expansion where the coverage should be maximal. This
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